Page 67 - GTM-1-1

Global Translational Medicine Fusion events identified in tumor

selpercatinib with crizotinib. Clin Cancer Res, 27(1): 34–42. https://doi.org/10.1016/j.jtho.2019.05.041
https://doi.org/10.1158/1078-0432.ccr-20-2278 102. Drilon A, Siena S, Dziadziuszko R, et al., 2020, Entrectinib in
96. Kulkarni A, Al-Hraishawi H, Simhadri S, et al., 2017, ROS1 fusion-positive non-small-cell lung cancer: Integrated
BRAF fusion as a novel mechanism of acquired resistance analysis of three phase 1-2 trials. Lancet Oncol, 21(2): 261–270.
to vemurafenib in BRAF(V600E) mutant melanoma. Clin 103. Drilon A, Nagasubramanian R, Blake JF, et al., 2017, A
Cancer Res, 23(18): 5631–5638. next-generation TRK kinase inhibitor overcomes acquired
https://doi.org/10.1158/1078-0432.ccr-16-0758 resistance to prior TRK kinase inhibition in patients with TRK
fusion-positive solid tumors. Cancer Discov, 7(9): 963–972.
97. Available from: https://www.foundationmedicine.com/
genomic-testing [Last accessed on 2019 Feb 01]. https://doi.org/10.1158/2159-8290.cd-17-0507
98. Song Z, Liu T, Shi L, et al., 2021, The deep learning model 104. Drilon A, Laetsch TW, Kummar S, et al., 2018, Efficacy of
combining CT image and clinicopathological information larotrectinib in TRK fusion-positive cancers in adults and
for predicting ALK fusion status and response to ALK-TKI children. N Engl J Med, 378(8): 731–739.
therapy in non-small cell lung cancer patients. Eur J Nucl 105. Hong DS, Bauer TM, Lee JJ, et al., 2019, Larotrectinib in adult
Med Mol Imaging, 48(2): 361–371.
patients with solid tumours: A multi-centre, open-label,
https://doi.org/10.1007/s00259-020-04986-6 phase I dose-escalation study. Ann Oncol, 30(2): 325–331.
99. Zhang Y, Li J, Yi K, et al., 2019, Elevated signature of a gene https://doi.org/10.1093/annonc/mdy539
module coexpressed with CDC20 marks genomic instability
in glioma. Proc Natl Acad Sci U S A, 116(14): 6975–6984. 106. Hong DS, DuBois SG, Kummar S, et al., 2020, Larotrectinib
in patients with TRK fusion-positive solid tumours:
https://doi.org/10.1073/pnas.1921769117 A pooled analysis of three phase 1/2 clinical trials. Lancet
100. Drilon A, Rekhtman N, Arcila M, et al., 2016, Cabozantinib Oncol, 21(4): 531–540.
in patients with advanced RET-rearranged non-small-cell https://doi.org/10.1016/s1470-2045(19)30856-3
lung cancer: An open-label, single-centre, phase 2, single-
arm trial. Lancet Oncol, 17(12): 1653–1660. 107. Zhao Z, Chen J, Bao Z, et al., 2020, Extensive MET
alterations confer clinical response to MET inhibitors in
https://doi.org/10.1016/s1470-2045(16)30562-9 gliomas. BioRxiv, 2020: 364711.

101. Aggarwal C, Redman MW, Lara PN Jr., et al., 2019, SWOG 108. Laetsch TW, DuBois SG, Mascarenhas L, et al., 2018,
S1400D (NCT02965378), a phase II study of the fibroblast Larotrectinib for paediatric solid tumours harbouring
growth factor receptor inhibitor AZD4547 in previously NTRK gene fusions: Phase 1 results from a multicentre,
treated patients with fibroblast growth factor pathway- open-label, phase 1/2 study. Lancet Oncol, 19(5): 705–714.
activated stage IV squamous cell lung cancer (lung-MAP
substudy). J Thorac Oncol, 14(10): 1847–1852. https://doi.org/10.1016/s1470-2045(18)30119-0

Volume 1 Issue 1 (2022) 12 https://doi.org/10.36922/gtm.v1i1.54